These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 32588337)

  • 1. The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments.
    Webb EJD; Meads D; Eskytė I; Ford HL; Bekker HL; Chataway J; Pepper G; Marti J; Okan Y; Pavitt SH; Schmierer K; Manzano A
    Patient; 2020 Oct; 13(5):583-597. PubMed ID: 32588337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices.
    Webb EJD; Meads D; Eskytė I; Ford HL; Bekker HL; Chataway J; Pepper G; Marti J; Okan Y; Pavitt SH; Schmierer K; Manzano A
    Patient; 2023 Sep; 16(5):457-471. PubMed ID: 37072663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summarizing Patient Preferences for the Competitive Landscape of Multiple Sclerosis Treatment Options.
    Jonker MF; Donkers B; Goossens LMA; Hoefman RJ; Jabbarian LJ; de Bekker-Grob EW; Versteegh MM; Harty G; Wong SL
    Med Decis Making; 2020 Feb; 40(2):198-211. PubMed ID: 32065023
    [No Abstract]   [Full Text] [Related]  

  • 4. Modeling the impact of patient treatment preference on health outcomes in relapsing-remitting multiple sclerosis.
    van Eijndhoven E; Brauer M; Kee R; MacEwan J; Mucha L; Wong SL; Durand A; Shafrin J
    J Med Econ; 2020 May; 23(5):474-483. PubMed ID: 31903813
    [No Abstract]   [Full Text] [Related]  

  • 5. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study.
    Villaverde-González R; Candeliere-Merlicco A; Alonso-Frías MA; Aparicio Castro E; Carrillo Alcaraz A; Mallada Frechín J; Pérez Sempere Á
    Mult Scler Relat Disord; 2020 Nov; 46():102518. PubMed ID: 32977075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis.
    Bottomley C; Lloyd A; Bennett G; Adlard N
    J Med Econ; 2017 Aug; 20(8):863-870. PubMed ID: 28562125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.
    Freeman L; Longbrake EE; Coyle PK; Hendin B; Vollmer T
    CNS Drugs; 2022 Dec; 36(12):1285-1299. PubMed ID: 36350491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients' Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice Experiment.
    Keenan A; Whichello C; Le HH; Kern DM; Fernandez GS; Turner V; Das A; Quaife M; Ross AP
    Patient; 2024 Nov; 17(6):685-696. PubMed ID: 38748388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices.
    Wilson L; Loucks A; Bui C; Gipson G; Zhong L; Schwartzburg A; Crabtree E; Goodin D; Waubant E; McCulloch C
    J Neurol Sci; 2014 Sep; 344(1-2):80-7. PubMed ID: 25037284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient and neurologist preferences in the UK for relapsing-remitting multiple sclerosis treatments: findings from a discrete choice experiment.
    Tencer T; Will O; Kumar J; Cambron-Mellott MJ; Mackie DS; Beusterien K
    Curr Med Res Opin; 2021 Sep; 37(9):1589-1598. PubMed ID: 34129418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis.
    Manzano A; Eskyté I; Ford HL; Pavitt SH; Potrata B; Schmierer K; Chataway J; Webb EJD; Meads D; Pepper G; Bekker HL
    Mult Scler Relat Disord; 2020 Nov; 46():102507. PubMed ID: 32979733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
    Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
    JAMA Neurol; 2018 Mar; 75(3):320-327. PubMed ID: 29309484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity.
    Juto A; Fink K; Al Nimer F; Piehl F
    Mult Scler Relat Disord; 2020 Jan; 37():101468. PubMed ID: 31683231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient and Neurologist Preferences in the United States for Relapsing-Remitting Multiple Sclerosis Treatments: Findings from a Discrete Choice Experiment.
    Kumar J; Cambron-Mellott MJ; Tencer T; Will O; Mackie DS; Beusterien K
    Patient Prefer Adherence; 2021; 15():1515-1527. PubMed ID: 34267507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients' preferences and willingness-to-pay for disease-modifying therapies.
    Frost N; Freeman J; Brixner D; Mort J; Clem J; Ngorsuraches S
    Mult Scler Relat Disord; 2019 Oct; 35():55-60. PubMed ID: 31323483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations.
    Hernandez L; O'Donnell M; Postma M
    Pharmacoeconomics; 2018 Oct; 36(10):1223-1252. PubMed ID: 29971666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing women's preferences for subsequent management in the event of incomplete evacuation of the uterus after misoprostol treatment for miscarriage.
    Hentzen JEKR; Verschoor MA; Lemmers M; Ankum WM; Mol BWJ; van Wely M
    Hum Reprod; 2017 Aug; 32(8):1674-1683. PubMed ID: 28575402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment.
    Poulos C; Kinter E; Yang JC; Bridges JF; Posner J; Reder AT
    Patient; 2016 Apr; 9(2):171-80. PubMed ID: 26259849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.